● Recruiting

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Condition: Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal Adenocarcinoma · Sponsor: Revolution Medicines, Inc.

PhasePhase 3

Planned participants500

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

This description comes directly from the study's public registry record.

Talk to the study team

Revolution Medicines Study Director · 1-844-2-REVMED · medinfo@revmed.com

Always discuss trial participation with your own doctor first.

Locations (43)

Cedars-Sinai Cancer at Cedars-Sinai Medical Center	Los Angeles, California, United States	Recruiting
University of California, Los Angeles	Los Angeles, California, United States	Recruiting
Stanford Cancer Institute	Palo Alto, California, United States	Recruiting
University of California, San Francisco	San Francisco, California, United States	Recruiting
Rocky Mountain Cancer Centers, LLP	Lakewood, Colorado, United States	Recruiting
Hartford Healthcare	Hartford, Connecticut, United States	Recruiting
Mayo Clinic	Jacksonville, Florida, United States	Recruiting
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center	Miami, Florida, United States	Recruiting
Winship Cancer Institute, Emory University	Atlanta, Georgia, United States	Recruiting
Community Health Network	Indianapolis, Indiana, United States	Recruiting
University of Kansas Medical Center Research Institute, Inc.	Lawrence, Kansas, United States	Recruiting
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins & Sibley Memorial Hospital	Baltimore, Maryland, United States	Recruiting

+ 31 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07252232